The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis’ JAKAFI and PharmaEssentia/AOP Orphan Pharmaceuticals’ BESREMi. In contrast, we also anticipate the…
